Study analysis · Annals of internal medicine · 2026
Your Ozempic weight loss might be mostly muscle — and dieting does the same thing.
Weight-loss drugs like Ozempic make you lose muscle just as much as dieting does — and we don’t know if it hurts your strength.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
In simple terms
This study looked at many different experiments where people took weight-loss drugs and measured how their bodies changed. It found that these drugs usually make people lose fat, but sometimes also make them lose muscle. But because the studies were done differently, we can't say for sure exactly how much muscle is lost every time.
What’s the bottom line?
This study looked at whether popular weight-loss drugs like semaglutide and tirzepatide cause more muscle loss than diet and exercise.
How strong is this study?
The researchers did a good job finding lots of studies and comparing them, but they couldn't add up all the numbers because the studies used different ways to measure muscle. That makes it harder to trust the exact numbers, so we should be careful not to treat the results as perfect facts.
35 / 100
- COI disclosureconflicts of interest not disclosed
- Data availability+35/35
- Code availabilitycode not shared
0 / 100
- Randomizationrandomization unclear
- Blindingblinding unclear
- Control groupno control group
- Sample sizeno sample size reported
- Follow-upno follow-up reported
100 / 100
77 / 100
- P-values+15/15
- Effect size+20/20
- Confidence intervals+15/15
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 546 / 100
Probability of being correct
The highest quality evidence. Systematic reviews and meta-analyses that pool randomized controlled trials, giving the most reliable summary of experimental evidence.
This design can establish causation. This is a systematic review of RCTs explicitly identified in the abstract, which allows for causal inference, but heterogeneity in methods and lack of meta-analysis reduce confidence.
No Conflicts
No conflicts of interest identified
No conflicts identified
The study explicitly states 'PRIMARY FUNDING SOURCE: None.' No author affiliations, industry ties, or competing interests are mentioned. The absence of funding and disclosure sections suggests transparency, though the lack of a formal COI statement prevents full confirmation.
Key takeaways
- 01
On average, about 28% of weight lost from these drugs came from muscle.
- 02
In 65% of the studies, muscle loss was over 25% of total weight lost.
- 03
About 38% of diet/exercise groups also lost more than 25% muscle.
- 04
Losing muscle during weight loss is common—even with dieting—but these drugs cause it at similar or higher rates, and we don’t know if it affects strength or daily function.
Surprising findings
- Nearly half of nonpharmacologic weight loss studies also exceeded the 25% muscle loss benchmark.People assume muscle loss only happens with drugs — but diet and exercise cause it just as often, challenging the narrative that ‘natural’ methods are safer.
Practical takeaways
If you're on an incretin drug, ask your doctor about strength training to preserve muscle — and request a body composition scan if possible.
This study didn’t measure function, so we don’t know if muscle loss harms health — and no long-term data exists.
low confidenceWhy this study matters
Muscle Loss Is Shockingly Common
In 65% of studies using incretin therapies, over 25% of total weight loss came from muscle — with a median of 28.3% of weight lost being muscle. Even in diet and exercise groups, 38% exceeded that same benchmark.
Most people think weight-loss drugs are ‘fat-burning’ miracles — but this shows they’re just as likely to strip away muscle as traditional dieting, which changes how we view their safety.
We Don’t Know If It Matters
Not a single study in this review measured physical function — so we have zero data on whether losing this much muscle affects strength, mobility, or daily life.
People are taking these drugs for years — but if they’re losing muscle and can’t lift groceries or climb stairs, no one’s tracking it.
Measurement Chaos Skews the Numbers
Studies used 4 different methods to measure muscle loss — BIA, DXA, CT, MRI — and each had different benchmarks (25% vs. 15%). This made meta-analysis impossible.
The same drug might look ‘worse’ or ‘better’ depending on the machine used — meaning published stats could be misleading.
Want the whole report?
Detailed mode opens the full scientific breakdown — every score component, the methodology, conflicts of interest, the evidence analysis behind each claim, and the raw study data.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
This study looked at whether popular weight-loss drugs like semaglutide and tirzepatide cause more muscle loss than diet and exercise.
Research results
On average, about 28% of weight lost from these drugs came from muscle. In 65% of the studies, muscle loss was over 25% of total weight lost. About 38% of diet/exercise groups also lost more than 25% muscle.
What this means - more context
Losing muscle during weight loss is common—even with dieting—but these drugs cause it at similar or higher rates, and we don’t know if it affects strength or daily function.
To evaluate body composition changes, particularly fat-free mass and muscle loss, in adults with obesity receiving incretin-based therapies versus nonpharmacologic interventions.
Incretin-based therapies led to greater weight loss and reductions in fat mass and visceral adiposity compared to placebo or lifestyle interventions. Median muscle-related loss accounted for 28.3% of total weight loss, exceeding a 25% benchmark in 65% of studies; similar muscle loss occurred in nearly half of nonpharmacologic weight loss studies. No studies reported physical function outcomes, and heterogeneity in measurement methods precluded meta-analysis.
Methods Used
Systematic review of 35 randomized controlled trials (median duration 26 weeks, median 78 participants) reporting body composition changes via BIA, DXA, CT, or MRI. Prespecified benchmarks for muscle loss were applied. No meta-analysis was performed due to methodological heterogeneity.
Main Finding
Incretin-based therapies resulted in greater weight loss and fat mass reduction than comparators. Median 28.3% of total weight loss was attributable to muscle-related indices, with 65% of studies exceeding a 25% benchmark; 38% of nonpharmacologic weight loss studies exceeded their respective benchmark. No physical function outcomes were reported.
Confidence Level
Limited - based on abstract only, full methodology not available
Study Flags
Red Flags
- •Full text not available - methodology details cannot be verified
- •Heterogeneous measurement methods precluded meta-analysis
- •No physical function outcomes reported
No biological mechanisms were identified in this study. This may be an epidemiological, observational, or survey-based study that reports associations rather than proposing causal biological pathways.
Surprising Findings
Nearly half of nonpharmacologic weight loss studies also exceeded the 25% muscle loss benchmark.
People assume muscle loss only happens with drugs — but diet and exercise cause it just as often, challenging the narrative that ‘natural’ methods are safer.
Practical Takeaways
If you're on an incretin drug, ask your doctor about strength training to preserve muscle — and request a body composition scan if possible.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 546 / 100
Probability of being correct
The highest quality evidence. Systematic reviews and meta-analyses that pool randomized controlled trials, giving the most reliable summary of experimental evidence.
Human Systematic Review
Subject
Moderate probability
on the GRADE evidence scale
This study looked at many different experiments where people took weight-loss drugs and measured how their bodies changed. It found that these drugs usually make people lose fat, but sometimes also make them lose muscle. But because the studies were done differently, we can't say for sure exactly how much muscle is lost every time.
No conflicts of interest were detected in this study. No score impact.
Strengths
- Systematic search across multiple databases
- Explicit inclusion of RCTs with prespecified outcomes
- Use of standardized benchmarks for muscle loss
Weaknesses
- Heterogeneous body composition methods precluded meta-analysis
- No meta-analysis performed despite pooling 35 studies
- Risk of bias assessment incomplete (only 42.9% rated low risk)
Methodology
Evidence Keywords
Statistical Reporting
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
This study looked at whether popular weight-loss drugs like semaglutide and tirzepatide cause more muscle loss than diet and exercise.
Research results
On average, about 28% of weight lost from these drugs came from muscle. In 65% of the studies, muscle loss was over 25% of total weight lost. About 38% of diet/exercise groups also lost more than 25% muscle.
What this means - more context
Losing muscle during weight loss is common—even with dieting—but these drugs cause it at similar or higher rates, and we don’t know if it affects strength or daily function.
To evaluate body composition changes, particularly fat-free mass and muscle loss, in adults with obesity receiving incretin-based therapies versus nonpharmacologic interventions.
Incretin-based therapies led to greater weight loss and reductions in fat mass and visceral adiposity compared to placebo or lifestyle interventions. Median muscle-related loss accounted for 28.3% of total weight loss, exceeding a 25% benchmark in 65% of studies; similar muscle loss occurred in nearly half of nonpharmacologic weight loss studies. No studies reported physical function outcomes, and heterogeneity in measurement methods precluded meta-analysis.
Methods Used
Systematic review of 35 randomized controlled trials (median duration 26 weeks, median 78 participants) reporting body composition changes via BIA, DXA, CT, or MRI. Prespecified benchmarks for muscle loss were applied. No meta-analysis was performed due to methodological heterogeneity.
Main Finding
Incretin-based therapies resulted in greater weight loss and fat mass reduction than comparators. Median 28.3% of total weight loss was attributable to muscle-related indices, with 65% of studies exceeding a 25% benchmark; 38% of nonpharmacologic weight loss studies exceeded their respective benchmark. No physical function outcomes were reported.
Confidence Level
Limited - based on abstract only, full methodology not available
Study Flags
Red Flags
- •Full text not available - methodology details cannot be verified
- •Heterogeneous measurement methods precluded meta-analysis
- •No physical function outcomes reported
No biological mechanisms were identified in this study. This may be an epidemiological, observational, or survey-based study that reports associations rather than proposing causal biological pathways.
Surprising Findings
Nearly half of nonpharmacologic weight loss studies also exceeded the 25% muscle loss benchmark.
People assume muscle loss only happens with drugs — but diet and exercise cause it just as often, challenging the narrative that ‘natural’ methods are safer.
Practical Takeaways
If you're on an incretin drug, ask your doctor about strength training to preserve muscle — and request a body composition scan if possible.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 546 / 100
Probability of being correct
The highest quality evidence. Systematic reviews and meta-analyses that pool randomized controlled trials, giving the most reliable summary of experimental evidence.
Human Systematic Review
Subject
Moderate probability
on the GRADE evidence scale
This study looked at many different experiments where people took weight-loss drugs and measured how their bodies changed. It found that these drugs usually make people lose fat, but sometimes also make them lose muscle. But because the studies were done differently, we can't say for sure exactly how much muscle is lost every time.
No conflicts of interest were detected in this study. No score impact.
Strengths
- Systematic search across multiple databases
- Explicit inclusion of RCTs with prespecified outcomes
- Use of standardized benchmarks for muscle loss
Weaknesses
- Heterogeneous body composition methods precluded meta-analysis
- No meta-analysis performed despite pooling 35 studies
- Risk of bias assessment incomplete (only 42.9% rated low risk)
Methodology
Evidence Keywords
Statistical Reporting
Scoring
How strong is this study?
The researchers did a good job finding lots of studies and comparing them, but they couldn't add up all the numbers because the studies used different ways to measure muscle. That makes it harder to trust the exact numbers, so we should be careful not to treat the results as perfect facts.
35 / 100
- COI disclosureconflicts of interest not disclosed
- Data availability+35/35
- Code availabilitycode not shared
0 / 100
- Randomizationrandomization unclear
- Blindingblinding unclear
- Control groupno control group
- Sample sizeno sample size reported
- Follow-upno follow-up reported
100 / 100
77 / 100
- P-values+15/15
- Effect size+20/20
- Confidence intervals+15/15
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 546 / 100
Probability of being correct
The highest quality evidence. Systematic reviews and meta-analyses that pool randomized controlled trials, giving the most reliable summary of experimental evidence.
This design can establish causation. This is a systematic review of RCTs explicitly identified in the abstract, which allows for causal inference, but heterogeneity in methods and lack of meta-analysis reduce confidence.
No Conflicts
No conflicts of interest identified
No conflicts identified
The study explicitly states 'PRIMARY FUNDING SOURCE: None.' No author affiliations, industry ties, or competing interests are mentioned. The absence of funding and disclosure sections suggests transparency, though the lack of a formal COI statement prevents full confirmation.